GM-CSF can hasten recovery of patients with relapsed Hodgkin's disease, at less cost.
D000380:Agranulocytosis / Q000517:prevention & control; D017046:Cost Savings; D003365:Costs and Cost Analysis; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use*; D006689:Hodgkin Disease / Q000191:economics / Q000628:therapy*; D006801:Humans; D007902:Length of Stay / Q000191:economics; D009364:Neoplasm Recurrence, Local / Q000628:therapy; D010919:Placebos
D010919:Placebos; D016178:Granulocyte-Macrophage Colony-Stimulating Factor